Evidence map›Paper›PMID 41251911›Full record

Trial reportAnnals of surgical oncology2026

A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.

Hironobu Suto, Minoru Oshima, Yasuhisa Ando, Hiroyuki Matsukawa, Shigeo Takahashi, Toru Shibata, Hideki Kamada, Hideki Kobara, Hiroyuki Okuyama, Akihito Tsuji and 2 more

Abstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hironobu SutoDepartment of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan. suto.hironobu@kagawa-u.ac.jp.ORCID http://orcid.org/0000-0001-8476-3985
Minoru OshimaDepartment of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Yasuhisa AndoDepartment of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Hiroyuki MatsukawaDepartment of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Shigeo TakahashiDepartment of Radiation Oncology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Toru ShibataDepartment of Radiation Oncology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Hideki KamadaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Hideki KobaraDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Hiroyuki OkuyamaDepartment of Clinical Oncology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Akihito TsujiDepartment of Clinical Oncology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Kensuke KumamotoDepartment of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Keiichi OkanoDepartment of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeoadjuvant chemoradiotherapy (NACRT) is increasingly used for pancreatic ductal adenocarcinoma (PDAC), yet the optimal regimen remains unclear. This phase II trial evaluated the feasibility and efficacy of a short-course NACRT regimen comprising gemcitabine, S-1, and hypofractionated radiotherapy in patients with resectable (R) or borderline resectable (BR) PDAC. PATIENTS AND

methodsPatients received NACRT with gemcitabine (1000 mg/m

resultsIn total, 54 patients were enrolled. Treatment completion ranged from 87 to 98%. Among 49 patients who underwent resection, 96% achieved R0 resection. A College of American Pathologists tumor regression score of 2 or lower was observed in 49% of tumors. Median follow-up was 24 months. In the intention-to-treat analysis, 1-, 3-, and 5-year overall survival rates were 78, 53, and 42%, respectively. Among resected patients, the median recurrence-free survival was 18 months. Patients with R-PDAC had survival comparable to those reported with longer NACRT regimens, while those with BR-PDAC had less favorable outcomes.

conclusionsThis short-course NACRT regimen was feasible and yielded favorable survival outcomes, achieving a high R0 resection rate in patients with R-PDAC. By contrast, patients with BR-PDAC may benefit from more intensive treatment, although this requires further validation. These findings support the clinical utility of short-course NACRT and highlight the importance of treatment stratification on the basis of resectability status.

Indexed as

AdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalNeoadjuvant TherapyPancreatic NeoplasmsAdultAgedChemoradiotherapyDeoxycytidineDrug CombinationsFemaleFollow-Up StudiesGemcitabineHumansMaleMiddle AgedDeoxycytidineDrug CombinationsGemcitabineOxonic AcidS 1 (combination)TegafurGemcitabineHypofractionated radiotherapyNeoadjuvant chemoradiotherapyPancreatic ductal adenocarcinomaS-1

Identifiers

PMID41251911

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.